Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9

Journal of Lipid Research

Volumn 56, Issue 11, 2015, Pages 2085-2093

  Van Der Tuin, Sam J L ^a   Kühnast, Susan ^a,b   Berbée, Jimmy F P ^a   Verschuren, Lars ^b   Pieterman, Elsbet J ^b   Havekes, Louis M ^a,b   Van Der Hoorn, José W A ^a,b   Rensen, Patrick C N ^a   Jukema, J Wouter ^a   Princen, Hans M G ^b   Willems Van Dijk, Ko ^a,b   Wang, Yanan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RNA; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; OXAZOLIDINONE DERIVATIVE; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME BLOOD LEVEL; FEMALE; LIVER; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ISOLATION; WESTERN DIET; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; DRUG EFFECTS; DYSLIPIDEMIAS; ENZYMOLOGY; GENE EXPRESSION; GENE REGULATORY NETWORK; LIPID METABOLISM; METABOLISM; PRECLINICAL STUDY; TRANSGENIC MOUSE;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, VLDL; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DYSLIPIDEMIAS; FEMALE; GENE EXPRESSION; GENE REGULATORY NETWORKS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; METABOLIC NETWORKS AND PATHWAYS; MICE, TRANSGENIC; OXAZOLIDINONES; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84948799852     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M057794     Document Type: Article

References (54)

1. Baigent, C., L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376: 1670-1681.
2. Davidson, M. H., K. C. Maki, T. A. Pearson, R. C. Pasternak, P. C. Deedwania, J. M. McKenney, G. C. Fonarow, D. J. Maron, B. J. Ansell, L. T. Clark, et al. 2005. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96: 556-563.
3. Di Angelantonio, E., N. Sarwar, P. Perry, S. Kaptoge, K. K. Ray, A. Thompson, A. M. Wood, S. Lewington, N. Sattar, C. J. Packard, et al. 2009. Major lipids, apolipoproteins, and risk of vascular disease. J. Am. Med. Assoc. 302: 1993-2000.
4. Tall, A. R. 1993. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34: 1255-1274.
5. Marotti, K. R., C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray, and G. W. Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364: 73-75.
6. Plump, A. S., L. Masucci-Magoulas, C. Bruce, C. L. Bisgaier, J. L. Breslow, and A. R. Tall. 1999. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cho-lesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19: 1105-1110.
7. ∗3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26: 2552-2559.
8. de Grooth, G. J., K. E. Zerba, S. P. Huang, Z. Tsuchihashi, T. Kirchgessner, R. Belder, P. Vishnupad, B. Hu, A. H. Klerkx, A. H. Zwinderman, et al. 2004. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J. Am. Coll. Cardiol. 43: 854-857.
9. Ridker, P. M., G. Pare, A. N. Parker, R. Y. Zee, J. P. Miletich, and D. I. Chasman. 2009. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2: 26-33.
10. Karalis, I., P. C. Rensen, and J. W. Jukema. 2013. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Circ. Cardiovasc. Qual. Outcomes. 6: 360-366.
11. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
12. Bloomfield, D., G. L. Carlson, A. Sapre, D. Tribble, J. M. McKenney, T. W. Littlejohn, III, C. M. Sisk, Y. Mitchel, and R. C. Pasternak. 2009. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157: 352-360.e2.
13. Nicholls, S. J., H. B. Brewer, J. J. Kastelein, K. A. Krueger, M. D. Wang, M. Shao, B. Hu, E. McErlean, and S. E. Nissen. 2011. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. J. Am. Med. Assoc. 306: 2099-2109.
14. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367: 2089-2099.
15. de Haan, W., J. de Vries-van der Weij, J. W. van der Hoorn, T. Gautier, C. C. van der Hoogt, M. Westerterp, J. A. Romijn, J. W. Jukema, L. M. Havekes, H. M. Princen, et al. 2008. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 117: 2515-2522.
16. U.S. National Institutes of Health. ClinicalTrials.gov. Accessed September 29, 2014, at http://www.clinicaltrials.gov.
17. de Knijff, P., A. M. van den Maagdenberg, A. F. Stalenhoef, J. A. Leuven, P. N. Demacker, L. P. Kuyt, R. R. Frants, and L. M. Havekes. 1991. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J. Clin. Invest. 88: 643-655.
18. ∗3-Leiden. CETP mice. Atherosclerosis. 197: 57-63.
19. van der Hoogt, C. C., W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. Princen, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2007. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J. Lipid Res. 48: 1763-1771.
20. ∗3 Leiden. CETP mice mainly by reducing non HDL-cholesterol. PLoS One. 8: e66467.
21. ∗3 Leiden. CETP mice. Arterioscler. Thromb. Vasc. Biol. 28: 2016-2022.
22. Kühnast, S., S. J. van der Tuin, J. W. van der Hoorn, J. B. van Klinken, B. Simic, E. Pieterman, L. M. Havekes, U. Landmesser, T. F. Lüscher, K. Willems van Dijk, et al. 2015. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cho-lesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur. Heart J. 36: 39-48.
23. Ason, B., J. W. van der Hoorn, J. Chan, E. Lee, E. J. Pieterman, K. K. Nguyen, M. Di, S. Shetterly, J. Tang, W. C. Yeh, et al. 2014. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J. Lipid Res. 55: 2370-2379.
24. Du, P., W. A. Kibbe, and S. M. Lin. 2008. lumi: a pipeline for pro-cessing Illumina microarray. Bioinformatics. 24: 1547-1548.
25. Wettenhall, J. M., and G. K. Smyth. 2004. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 20: 3705-3706.
26. van den Maagdenberg, A. M., M. H. Hofker, P. J. Krimpenfort, I. de Bruijn, B. van Vlijmen, H. van der Boom, L. M. Havekes, and R. R. Frants. 1993. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268: 10540-10545.
27. Kühnast, S., J. W. van der Hoorn, E. J. Pieterman, A. M. van den Hoek, W. J. Sasiela, V. Gusarova, A. Peyman, H. L. Schäfer, U. Schwahn, J. W. Jukema, et al. 2014. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res. 55: 2103-2112.
28. Aalto-Setälä, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
29. Redgrave, T. G., D. C. Roberts, and C. E. West. 1975. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65: 42-49.
30. Li, X., F. Catalina, S. M. Grundy, and S. Patel. 1996. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J. Lipid Res. 37: 210-220.
31. Rensen, P. C., M. C. van Dijk, E. C. Havenaar, M. K. Bijsterbosch, J. K. Kruijt, and T. J. van Berkel. 1995. Selective liver targeting of antivirals by recombinant chylomicrons-a new therapeutic approach to hepatitis B. Nat. Med. 1: 221-225.
32. Rensen, P. C., N. Herijgers, M. H. Netscher, S. C. Meskers, M. van Eck, and T. J. van Berkel. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38: 1070-1084.
33. Jong, M. C., P. C. Rensen, V. E. Dahlmans, H. van der Boom, T. J. van Berkel, and L. M. Havekes. 2001. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 42: 1578-1585.
34. Zhang, L., T. McCabe, J. H. Condra, Y. G. Ni, L. B. Peterson, W. Wang, A. M. Strack, F. Wang, S. Pandit, H. Hammond, et al. 2012. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int. J. Biol. Sci. 8: 310-327.
35. Prabhu, A. V., L. J. Sharpe, and A. J. Brown. 2014. The sterol-based transcriptional control of human 7-dehydrocholesterol reductase (DHCR7): evidence of a cooperative regulatory program in cholesterol synthesis. Biochim. Biophys. Acta. 1842: 1431-1439.
36. Bennati, A. M., M. Castelli, M. A. Della Fazia, T. Beccari, D. Caruso, G. Servillo, and R. Roberti. 2006. Sterol dependent regulation of human TM7SF2 gene expression: role of the encoded 3beta-hydroxysterol Delta14-reductase in human cholesterol biosynthesis. Biochim. Biophys. Acta. 1761: 677-685.
37. Jeong, H. J., H. S. Lee, K. S. Kim, Y. K. Kim, D. Yoon, and S. W. Park. 2008. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J. Lipid Res. 49: 399-409.
38. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
39. Park, S. W., Y. A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279: 50630-50638.
40. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101: 7100-7105.
41. Canuel, M., X. Sun, M. C. Asselin, E. Paramithiotis, A. Prat, and N. G. Seidah. 2013. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One. 8: e64145.
42. Berbée, J. F., M. R. Boon, P. P. Khedoe, A. Bartelt, C. Schlein, A. Worthmann, S. Kooijman, G. Hoeke, I. M. Mol, C. John, et al. 2015. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nat. Commun. 6: 6356.
43. Roddy, T. P., D. G. McLaren, Y. Chen, D. Xie, K. Dunn, A. Kulick, D. Szeto, G. Forrest, K. Albanese, M. Donnelly, et al. 2014. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques. Eur. J. Pharmacol. 740: 410-416.
44. Dong, B., A. B. Singh, C. Fung, K. Kan, and J. Liu. 2014. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 235: 449-462.
45. Norata, G. D., G. Tibolla, and A. L. Catapano. 2014. Targeting PCSK9 for hypercholesterolemia. Annu. Rev. Pharmacol. Toxicol. 54: 273-293.
46. Stein, E. A., and F. Raal. 2014. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu. Rev. Med. 65: 417-431.
47. Brown, M. S., and J. L. Goldstein. 1999. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA. 96: 11041-11048.
48. Dietschy, J. M., S. D. Turley, and D. K. Spady. 1993. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34: 1637-1659.
49. Millar, J. S., M. E. Brousseau, M. R. Diffenderfer, P. H. Barrett, F. K. Welty, J. S. Cohn, A. Wilson, M. L. Wolfe, C. Nartsupha, P. M. Schaefer, et al. 2008. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism. J. Lipid Res. 49: 543-549.
50. Millar, J. S., M. E. Brousseau, M. R. Diffenderfer, P. H. Barrett, F. K. Welty, A. Faruqi, M. L. Wolfe, C. Nartsupha, A. G. Digenio, J. P. Mancuso, et al. 2006. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler. Thromb. Vasc. Biol. 26: 1350-1356.
51. Timsit, Y. E., and M. Negishi. 2007. CAR and PXR: the xenobiotic-sensing receptors. Steroids. 72: 231-246.
52. Cannon, C. P., S. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, et al. 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363: 2406-2415.
53. Krishna, R., M. S. Anderson, A. J. Bergman, B. Jin, M. Fallon, J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D. M. Bloomfield, et al. 2007. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two doubleblind, randomised placebo-controlled phase I studies. Lancet. 370: 1907-1914.
54. Krishna, R., A. J. Bergman, B. Jin, M. Fallon, J. Cote, P. Van Hoydonck, T. Laethem, I. N. Gendrano 3rd, K. Van Dyck, D. Hilliard, et al. 2008. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84: 679-683.